STGI news today...
Aids Research Alliance and Steroidogenesis Inhibitors Announce Start Of HIV Study With Anticort
Business Wire - March 08, 1999 10:57
LAS VEGAS--(BW HealthWire)--March 8, 1999--Aids Research Alliance and Steroidogenesis Inhibitors International (OTCBB:STGI) today jointly announced the start of an HIV treatment study with ANTICORT(TM), a drug developed by STGI.
ANTICORT, an anticortisol, immunomodulator drug, will be evaluated in HIV positive patients under anti-HIV therapy, to determine its potential effect on various immune systems. In its initial phase, ANTICORT will be administered under different regimens, intended to ascertain its safety and eventual first indications of its clinical effectiveness.
Gregg S. Britt, Chief Executive Officer of AIDS Research Alliance, stated, "Although significant advances have been made recently in the treatment of HIV disease, currently available anti-HIV drugs have significant shortcomings. Therefore, the pursuit of more effective, better-tolerated treatments is essential. We are pleased to be working with STGI in evaluating the effects of Anticort in HIV-infected individuals."
AIDS RESEARCH Alliance is a non-profit AIDS research organization dedicated to accelerating the discovery and development of effective treatments for HIV/AIDS and a vaccine to prevent new infections.
STGI is a pharmaceutical R&D Corporation, engaged in the development of anticortisol drugs to be used in diseases/condtions associated with elevated levels of the immunosuppressive hormone cortisol. STGI's flagship anticortisol drug, ANTICORT, has been approved by the FDA to be clinically tested in an HIV population - a condition often associated with "high cortisol" that is apparently playing a major role in the destruction of the immune system as encountered in HIV+ and AIDS.
Dr. Alfred T. Sapse, President, stated, " STGI is pleased to announce the commencement of this important clinical study, and is looking forward to its results."
This release may include "forward-looking statement" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1034. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable it can give no assurance that such expectations will prove correct. This is neither an offer to buy or sell a security. For informational purposes only, from sources deemed to be reliable. For more information visit our World Wide Web page at www.anticort.com.
CONTACT: STEROIDOGENESIS
Janet Greeson, Ph.D.
(702) 735-7001
or
PERFORMANCE STRATEGIES
Richard L. Brown/Chuck Jordan
(303) 471-5943
or
H.L. LANZET INC.
Herbert Lanzet/DeeDee Lanzet
(212) 687-0061
Headlines Next Story
--------------------------------------------------------------------------------
%NV-STEROIDOGENESIS STGI %NEVADA %MEDICINE %BIOTECHNOLOGY %PRODUCT V%BW P%BW
Click Here For More Information
|
